Clobetasol Propionate
FDA-approved product (cream, topical), marketed as Byqlovi, Clobetasol Propionate, Clobetasol Propionate (Emollient) and 10 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Psoriasis
- Psoriasis vulgaris
- Skin disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids, very potent (group iv)
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Clobetasol Propionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis
NCT00400725 · start 2006-09-29
Registered record
- Registry ID
- NCT00400725
- Conditions
- Scalp Psoriasis
- Interventions
- Clobex® Shampoo; Clobex® Vehicle Shampoo; Clobex® Shampoo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-09-29
- Completion
- 2007-08-20
- Enrolment
- 288
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionScalp PsoriasisInterventionClobex® Shampoo; Clobex® Vehicle Shampoo; Clobex® ShampooPhasePhase 3Registry statusCompletedEfficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis
NCT00437216 · start 2006-02
Registered record
- Registry ID
- NCT00437216
- Conditions
- Psoriasis
- Interventions
- Clobetasol Propionate, 0.05%; Clobetasol propionate, 0.05% Spray
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2006-02
- Completion
- 2006-07
- Enrolment
- 2,488
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPsoriasisInterventionClobetasol Propionate, 0.05%; Clobetasol propionate, 0.05% SprayPhaseNot recordedRegistry statusCompletedPivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects
NCT00864500 · start 2005-11
Registered record
- Registry ID
- NCT00864500
- Conditions
- Healthy
- Interventions
- Clobetasol Propionate 0.05% lotion, single exposure; Clobex TM 0.05% Lotion, single exposure
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2005-11
- Completion
- 2006-02
- Enrolment
- 224
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionClobetasol Propionate 0.05% lotion, single exposure; Clobex TM 0.05% Lotion, single exposurePhasePhase 1Registry statusCompletedHydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus
NCT00102557 · start 2005-01
Registered record
- Registry ID
- NCT00102557
- Conditions
- Lichen Planus, Oral
- Interventions
- Hydroxychloroquine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-01
- Completion
- 2005-10
- Enrolment
- 74
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLichen Planus, OralInterventionHydroxychloroquinePhasePhase 2Registry statusCompletedValacyclovir+Temovate Gel for the Treatment of Herpes Labialis
NCT00297011 · start 2004-09
Registered record
- Registry ID
- NCT00297011
- Conditions
- Herpes Labialis
- Interventions
- valacyclovir+clobetasol gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-09
- Completion
- 2008-01
- Enrolment
- 300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHerpes LabialisInterventionvalacyclovir+clobetasol gelPhasePhase 2Registry statusCompleted